Lalla F R, Ning J, Chang T M
Artificial Cells and Organs Research Centre, McGill University, Montreal, Quebec, Canada.
Biomater Artif Cells Artif Organs. 1989;17(3):363-9. doi: 10.3109/10731198909118292.
Although polyhemoglobin produced from homologous sources is not immunogenic when utilized in vivo (1), effects on hemostasis and thrombosis have not been documented. In this study, we use rat platelet rich plasma (PRP) and light transmission aggregometry to measure the possible influence of stroma-free hemoglobin (SFHb) and pyridoxalated polyhemoglobin (PP-PolyHb) on platelet aggregation in response to various levels of adenosine triphosphate (ADP) activation in vitro. Our study demonstrates that PP-PolyHb and SFHb solutions, when added to PRP in volumes and concentrations likely to be administered to patients requiring perfusant therapy, do not initiate or facilitate platelet activation. Both solutions induce similar levels of aggregation (and presumably activation) inhibition, but do so only at high or maximal levels of ADP activator stimulation, late in the aggregation sequence. The apparent inability of the purified hemoglobins to stimulate platelets is a necessary characteristic if such preparations are to be used as clinical perfusants in hemorrhagic emergencies.
尽管同源来源产生的多聚血红蛋白在体内使用时不具有免疫原性(1)，但其对止血和血栓形成的影响尚未见文献报道。在本研究中，我们使用大鼠富血小板血浆(PRP)和光透射聚集法，来测量无基质血红蛋白(SFHb)和吡哆醛化多聚血红蛋白(PP - PolyHb)在体外对不同水平三磷酸腺苷(ADP)激活反应下血小板聚集的可能影响。我们的研究表明，当以可能用于需要灌注治疗患者的体积和浓度添加到PRP中时，PP - PolyHb和SFHb溶液不会引发或促进血小板激活。两种溶液诱导的聚集(以及推测的激活)抑制水平相似，但仅在聚集序列后期、ADP激活剂刺激的高水平或最大水平时才会如此。如果要将此类纯化血红蛋白制剂用作出血性紧急情况的临床灌注剂，其明显无法刺激血小板是一个必要特性。
